Aarti Pharmalabs Share Price

NSE
AARTIPHARM •
BUY
The current prices are delayed, login or Open Demat Account for live prices.
Aarti Pharmalabs Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Aarti Pharmalabs Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
Near 52W High of ₹837.25
12.8
Dividend yield 1yr %
Below industry Median
0.4

Aarti Pharmalabs Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Aarti Pharmalabs Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
563.78 Cr
537.78 Cr
458.03 Cr
555.49 Cr
505.77 Cr

Aarti Pharmalabs Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022
2125.19 Cr
1857.5 Cr
1947.55 Cr
1202.46 Cr

Aarti Pharmalabs Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
88.34 Cr
73.99 Cr
54.62 Cr
55.45 Cr
65.25 Cr

Aarti Pharmalabs Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022
272.4 Cr
216.9 Cr
193.49 Cr
122.25 Cr
Aarti Pharmalabs Result Highlights
  • Aarti Pharmalabs Ltd reported a 6.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 4.5%.

  • Its expenses for the quarter were down by 6.8% QoQ and 3.5% YoY.

  • The net profit decreased 11.8% QoQ and increased 52.2% YoY.

  • The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 7.2 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Aarti Pharmalabs shareholding Pattern

Promoter
44.3%
Foreign Institutions
7.4%
Mutual Funds
0.8%
Domestic Institutions
7.5%
Public
40.8%
Promoter
44.7%
Foreign Institutions
8.6%
Mutual Funds
3.9%
Domestic Institutions
10.4%
Public
36.3%
Promoter
46.1%
Foreign Institutions
7.4%
Mutual Funds
4.9%
Domestic Institutions
11.3%
Public
35.2%
Promoter
46.5%
Foreign Institutions
7.1%
Mutual Funds
4.7%
Domestic Institutions
11.5%
Public
35%
Promoter
46.5%
Foreign Institutions
8.3%
Mutual Funds
2.7%
Domestic Institutions
10%
Public
35.2%
Promoter
46.5%
Foreign Institutions
8.2%
Mutual Funds
2%
Domestic Institutions
9.9%
Public
35.4%

Aarti Pharmalabs Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
781.60
10Day EMA
761.50
12Day EMA
756.50
20Day EMA
745.00
26Day EMA
740.60
50Day EMA
729.00
100Day EMA
706.20
200Day EMA
665.30
5Day SMA
780.30
10Day SMA
746.30
20Day SMA
737.50
30Day SMA
728.30
50Day SMA
735.20
100Day SMA
699.40
150Day SMA
675.80
200Day SMA
666.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
254841 Rs
623260 Rs
Week Rs
355784 Rs
923542 Rs
Month Rs
198557 Rs
509522 Rs
Resistance & Support
802.67
Pivot
Resistance
First Resistance
827.28
Second Resistance
843.62
Third Resistance
868.23
Support
First Support
786.33
Second support
761.72
Third Support
745.38
Relative Strength Index
63.60
Money Flow Index
84.94
MACD
15.93
MACD Signal
5.97
Average True Range
40.81
Average Directional Index
12.65
Rate of Change (21)
29.88
Rate of Change (125)
17.85

Aarti Pharmalabs Latest News

12 MAY 2025 | Monday

Aarti Pharmalabs Ltd - 543748 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

12 MAY 2025 | Monday

Q4FY25 &FY25 Result Announced for Aarti Pharmalabs Ltd.

12 MAY 2025 | Monday

Aarti Pharmalabs Ltd - 543748 - Announcement under Regulation 30 (LODR)-Newspaper Publication

View More

Aarti Pharmalabs Company background

Founded in: 2019
Managing director: Narendra Jagannath Salvi
Aarti Pharmachem Limited was incorporated as a Public Limited Company in 2019. The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives situated in India.In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005 commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022.The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021. Pursuant to the said Demerger Scheme, Aarti Industries Limited hived off its Pharmaceutical Division into a separate entity Aarti Pharmalabs Limited and accordingly, all the assets and liabilities pertaining to the Pharma Business Undertaking got transferred and vested into the Company effective from the above said Date.Thereafter, the Company in 2023 commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023.9,06,26,008 Equity Shares of Rs 5/ each got listed effective January 30, 2023.
Read More

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹816.55 in NSE and ₹810.1 in BSE as on 14/5/2025.

Aarti Pharmalabs share price in the past 1-year return was 38.13. The Aarti Pharmalabs share hit a 1-year low of Rs. 497.05 and a 1-year high of Rs. 837.25.

The market cap of Aarti Pharmalabs is Rs. 7350.01 Cr. as of 14/5/2025.

The PE ratios of Aarti Pharmalabs is 28.53 as of 14/5/2025.

The PB ratios of Aarti Pharmalabs is 3.98 as of 14/5/2025

The Mutual Fund Shareholding in Aarti Pharmalabs was 0.78% at the end of 14/5/2025.

You can easily buy Aarti Pharmalabs shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Aarti Pharmalabs stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -